Notice: This CMS-approved document has been submitted - Philips ...
Notice: This CMS-approved document has been submitted - Philips ... Notice: This CMS-approved document has been submitted - Philips ...
CMS-1403-FC being taken, the kinds and number of small entities the rule affects, and an explanation of any meaningful options that achieve the objectives with less significant adverse economic impact on the small entities. For purposes of the RFA, physicians, NPPs, and suppliers including IDTFs are considered small businesses if they generate revenues of $7 million or less based on SBA size standards. Approximately 95 percent of physicians are considered to be small entities. There are about 980,000 physicians, other practitioners, and medical suppliers that receive Medicare payment under the PFS. For purposes of the RFA, approximately 85 percent of suppliers of durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) are considered small businesses according to the Small Business Administration’s (SBA) size standards. We estimate that approximately 66,000 entities bill Medicare for DMEPOS each year. Total annual estimated Medicare revenues for DMEPOS suppliers are approximately $10.8 billion in 2007 for which $8.3 billion was for fee-for-service and $2.5 billion was for managed care. However the therapeutic shoe, oxygen and oxygen equipment, and low vision aids provisions in this rule do not have a significant economic impact on a substantial number of small entities. In the case of therapeutic 1032
CMS-1403-FC shoes, the regulation is being updated to reflect the fact that fee schedules were implemented on January 1, 2005, in accordance with the requirements of MMA section 627. Since the fees themselves are not impacted by this change, suppliers are likewise not impacted by this change. In the 1033 case of oxygen and oxygen equipment, as explained in section S.9. below, it is difficult to estimate the impact of section 144(b) of the MIPPA on small entities and oxygen and oxygen equipment suppliers in general. Nevertheless, we do believe that the net impact on small entities and other suppliers of oxygen and oxygen equipment will be positive rather than negative. This is based on the fact that this change allows suppliers to retain ownership of oxygen equipment in all cases when it is no longer needed by the beneficiary. Prior to this change, suppliers were required to relinquish ownership of oxygen equipment after 36 continuous rental months. While suppliers will be required to continue furnishing the equipment after the 36-month rental period for up to 2 additional years in some cases until the 5 year reasonable useful lifetime of the equipment ends, they will retain ownership of equipment when it is no longer needed and can furnish the equipment to other patients. Although suppliers will not be paid for non- routine maintenance or repair of oxygen equipment they own and furnish to Medicare beneficiaries, the equipment itself is very dependable and requires very little maintenance and servicing, so this change should not significantly impact
- Page 981 and 982: CMS-1403-FC Table 44: Calculation o
- Page 983 and 984: CMS-1403-FC XI. Payment for Certain
- Page 985 and 986: CMS-1403-FC In the Competitive Acqu
- Page 987 and 988: CMS-1403-FC glasses, hand magnifier
- Page 989 and 990: CMS-1403-FC Our interpretation of t
- Page 991 and 992: CMS-1403-FC Response: We understand
- Page 993 and 994: CMS-1403-FC defines “eyeglass”
- Page 995 and 996: CMS-1403-FC this statutory exclusio
- Page 997 and 998: CMS-1403-FC advances in the use of
- Page 999 and 1000: CMS-1403-FC is paid for his or her
- Page 1001 and 1002: CMS-1403-FC XII. Provisions of the
- Page 1003 and 1004: CMS-1403-FC these RUC recommendatio
- Page 1005 and 1006: CMS-1403-FC services. We believe a
- Page 1007 and 1008: CMS-1403-FC Section 144(b) of the M
- Page 1009 and 1010: CMS-1403-FC rulemaking with respect
- Page 1011 and 1012: CMS-1403-FC (respectively) of this
- Page 1013 and 1014: CMS-1403-FC completing and submitti
- Page 1015 and 1016: CMS-1403-FC §424.516(d)(1). Additi
- Page 1017 and 1018: CMS-1403-FC to several associated i
- Page 1019 and 1020: CMS-1403-FC incentive payment for 2
- Page 1021 and 1022: CMS-1403-FC year of PQRI reporting)
- Page 1023 and 1024: CMS-1403-FC Based on the assumption
- Page 1025 and 1026: CMS-1403-FC these activities for th
- Page 1027 and 1028: CMS-1403-FC per hour, we estimate t
- Page 1029 and 1030: CMS-1403-FC Because of the large nu
- Page 1031: CMS-1403-FC threshold, and hence al
- Page 1035 and 1036: CMS-1403-FC with comment period for
- Page 1037 and 1038: CMS-1403-FC substance of State laws
- Page 1039 and 1040: CMS-1403-FC $20 million from what e
- Page 1041 and 1042: CMS-1403-FC ● Impact of Work RVU
- Page 1043 and 1044: CMS-1403-FC imaging services from t
- Page 1045 and 1046: CMS-1403-FC ● Impact of section 1
- Page 1047 and 1048: CMS-1403-FC management, could have
- Page 1049 and 1050: CMS-1403-FC Table 50 illustrates, f
- Page 1051 and 1052: CMS-1403-FC CPT/ HCPCS Mod Descript
- Page 1053 and 1054: CMS-1403-FC impact associated with
- Page 1055 and 1056: CMS-1403-FC The fourth column shows
- Page 1057 and 1058: CMS-1403-FC the CY 2007 claims. The
- Page 1059 and 1060: CMS-1403-FC 1059 4/This column show
- Page 1061 and 1062: CMS-1403-FC requirements is to allo
- Page 1063 and 1064: CMS-1403-FC This amendment of the e
- Page 1065 and 1066: CMS-1403-FC 4 minutes per call, lab
- Page 1067 and 1068: CMS-1403-FC e-prescribing and who m
- Page 1069 and 1070: CMS-1403-FC anti-markup provisions
- Page 1071 and 1072: CMS-1403-FC approximately $50 per h
- Page 1073 and 1074: CMS-1403-FC e-prescribing measure i
- Page 1075 and 1076: CMS-1403-FC we estimate that each e
- Page 1077 and 1078: CMS-1403-FC P. Prohibition Concerni
- Page 1079 and 1080: CMS-1403-FC that provides a calcula
- Page 1081 and 1082: CMS-1403-FC treatment) that occur a
<strong>CMS</strong>-1403-FC<br />
being taken, the kinds and number of small entities the<br />
rule affects, and an explanation of any meaningful options<br />
that achieve the objectives with less significant adverse<br />
economic impact on the small entities.<br />
For purposes of the RFA, physicians, NPPs, and<br />
suppliers including IDTFs are considered small businesses<br />
if they generate revenues of $7 million or less based on<br />
SBA size standards. Approximately 95 percent of physicians<br />
are considered to be small entities. There are about<br />
980,000 physicians, other practitioners, and medical<br />
suppliers that receive Medicare payment under the PFS.<br />
For purposes of the RFA, approximately 85 percent of<br />
suppliers of durable medical equipment, prosthetics,<br />
orthotics and supplies (DMEPOS) are considered small<br />
businesses according to the Small Business Administration’s<br />
(SBA) size standards. We estimate that approximately<br />
66,000 entities bill Medicare for DMEPOS each year. Total<br />
annual estimated Medicare revenues for DMEPOS suppliers are<br />
approximately $10.8 billion in 2007 for which $8.3 billion<br />
was for fee-for-service and $2.5 billion was for managed<br />
care. However the therapeutic shoe, oxygen and oxygen<br />
equipment, and low vision aids provisions in this rule do<br />
not have a significant economic impact on a substantial<br />
number of small entities. In the case of therapeutic<br />
1032